Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$11.3 million.

  • Cardiff Oncology's Income from Continuing Operations rose 507.59% to -$11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.4 million, marking a year-over-year decrease of 1745.82%. This contributed to the annual value of -$45.4 million for FY2024, which is 979.37% down from last year.
  • Cardiff Oncology's Income from Continuing Operations amounted to -$11.3 million in Q3 2025, which was up 507.59% from -$13.9 million recorded in Q2 2025.
  • Cardiff Oncology's Income from Continuing Operations' 5-year high stood at -$5.4 million during Q1 2021, with a 5-year trough of -$13.9 million in Q2 2025.
  • Its 5-year average for Income from Continuing Operations is -$10.3 million, with a median of -$10.4 million in 2022.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first tumbled by 10349.14% in 2022, then soared by 1696.81% in 2024.
  • Quarter analysis of 5 years shows Cardiff Oncology's Income from Continuing Operations stood at -$9.5 million in 2021, then increased by 1.41% to -$9.4 million in 2022, then grew by 0.72% to -$9.3 million in 2023, then dropped by 26.39% to -$11.8 million in 2024, then grew by 4.47% to -$11.3 million in 2025.
  • Its Income from Continuing Operations was -$11.3 million in Q3 2025, compared to -$13.9 million in Q2 2025 and -$13.4 million in Q1 2025.